Depression therapy firm Flow closes Series A investment round
Summary
The planned expansion follows Flow’s success in treating patients across the UK and EU for the past two years, with its headset that delivers gentle stimulation using the tDCS technique to combat depression. The Swedish born medtech company founded by clinical psychologist Daniel Månsson, and neuroscientist Erik Rehn has grown from humble beginnings to fill the treatment gap between medication and therapy, with its first solution - the Flow headset. The cross-continental participants will fuel Flow Neuroscience’s core mission to create innovative treatments for mental health disorders that have no side effects, are easily accessible and empower patients and clinicians. Michael Rieger, head innovation operations & portfolio at CSS GroupCSS Group said: “Flow offers completely new ways of treating clinical depression by applying a technology that has not been available to the general public until now. Daniel Månsson, clinical psychologist and co-founder of Flow Neuroscience, said: “With accessibility at the forefront, we have a three-fold mission at Flow over the coming years; to advance our current treatment to be more patient-specific and to treat more people suffering from depression; To accelerate our collaboration with healthcare systems to provide alternative options for clinicians to prescribe and a complementary solution to reduce waiting times; And, to work in collaboration with researchers in the field of tDCS to validate further self-managed treatment solutions for a wider range of mental health disorders, such as anxiety.”